Multiply Labs develops robotic systems that automate manual steps in biologics manufacturing, making advanced therapies more accessible.
multiplylabs.comSan FranciscoBiotechYC S16Founded 201665 People (and 1 robot)
35 sources · checked 1 time, last 44d ago
Sources agree on the round details. The stated total capital raised is cumulative since founding, not this financing's running Series B total.
2 sources
The release dateline fixes the announcement at April 14, 2021, despite the page metadata showing a May 9, 2021 publication date. Founders Fund is named as Pathfinder’s vehicle, not as a separate round investor.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $75M $100M to date | 2026-10-06 | NantWorks, Patrick Soon-Shiong | No recent discussion |
35 sources · checked 1 time, last 44d ago [ VERIFIED ] read against 4 of 35 sources Sources agree on the round details. The stated total capital raised is cumulative since founding, not this financing's running Series B total. | ||||
Multiply Labs builds robotic clusters that automate cell and gene therapy manufacturing for pharmaceutical and biotech companies.
LinkedIn via Alexandria from ycombinator.com
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $20M $25M to date | 2021-04-14 | Casdin Capital | No recent discussion |
2 sources [ VERIFIED · CORRECTED ] read against 1 of 2 sources
The release dateline fixes the announcement at April 14, 2021, despite the page metadata showing a May 9, 2021 publication date. Founders Fund is named as Pathfinder’s vehicle, not as a separate round investor. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: businesswire.com, therobotreport.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]founders and batch from Y Combinator via Alexandria·[ AGENT ]company research by the Firecrawl agent | ||||
Manual manufacturing of advanced cell therapies is labor-intensive, expensive, slow, and vulnerable to contamination, while the company says its enclosed robotic systems can automate those steps and make therapies more accessible. The $75 million Series B brings total funding to more than $100 million and is intended to expand manufacturing capacity, product development, and engineering, regulatory, and commercial teams as Multiply Labs moves from clinical-stage deployments toward commercial production.
Checked against 10 sources on Oct 6
Also named as backers in company research: MIT Sandbox Innovation Fund Program, Y Combinator, Dr. Patrick Soon-Shiong